• Publications
  • Influence
In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug
SummaryThe anti-tumour effects and mechanism of action of combretastatin A-4 and its prodrug, combretastatin A-4 disodium phosphate, were examined in subcutaneous and orthotopically transplantedExpand
A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion.
Bryostatin 1 is a macrocyclic lactone derived from the marine invertebrate Bugula neritina. In vitro, bryostatin 1 activates protein kinase C (PKC), induces the differentiation of a number of cancerExpand
A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma
Bryostatin 1 is a naturally occurring macrocyclic lactone with promising antitumour and immunomodulatory function in preclinical and phase I clinical investigations. In this phase II study, 17Expand
Bryostatin 1-tamoxifen combinations show synergistic effects on the inhibition of growth of P388 cells in vitro.
This study shows that combinations of bryostatin 1, a novel modulator of protein kinase C currently under clinical evaluation, with the anti-oestrogenic agent tamoxifen caused a large synergisticExpand
Interaction of the novel agent amphethinile with tubulin.
The novel agent amphethinile is shown to inhibit tubulin assembly in vitro. This agent is capable of displacing colchicine but not vinblastine from tubulin and causes a stimulation in GTPase activityExpand
Phase I and pharmacologic study of CT-2584 HMS, a modulator of phosphatidic acid, in adult patients with solid tumours
CT-2584 HMS, 1-(11-dodecylamino-10-hydroxyundecyl)-3,7-dimethylxanthine-hydrogen methanesulphonate, is a modulator of intracellular phosphatidic acid. We treated 30 patients as part of a Phase I andExpand
Poster presentations
P1 ALTERED PATTERNS OF HEPARAN SULPHATE PROTEOGLYCAN EXPRESSION IN HUMAN EPITHELIAL OVARIAN CANCER EJ Davies1, A McGown1, J Shanks2, G David3, JT Gallagher4 and G Jayson4, 1Department of DrugExpand